Skip to main content
Erschienen in: European Archives of Psychiatry and Clinical Neuroscience 3/2015

01.04.2015 | Original Paper

Assessment of potential cardiovascular risks of methylphenidate in comparison with sibutramine: do we need a SCOUT (trial)?

verfasst von: Jochen Antel, Özgür Albayrak, Gerd Heusch, Tobias Banaschewski, Johannes Hebebrand

Erschienen in: European Archives of Psychiatry and Clinical Neuroscience | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Abstract

With the recent approval of methylphenidate (MPH) for treating attention-deficit/hyperactivity disorder (ADHD) in adults, the number of patients exposed will increase tremendously. The ongoing debate on the cardiovascular safety of MPH has triggered two large retrospective cohort studies in children and adolescents as well as in young to middle-aged adults. These studies looked into serious cardiovascular events (sudden cardiac death, acute myocardial infarction and stroke) as primary endpoints and concluded that MPH was safe after a mean duration of 2.1 years of follow-up in children and adolescents and mean duration of 0.33 years of current use in adults. The results are encouraging with respect to the short- and medium-term use of MPH. Without the inherent limitations of retrospective cohort studies, a prospective randomized, double-blind, placebo-controlled, multicenter trial in individuals stratified for cardiovascular risk factors would allow for an optimized risk assessment. With many millions of patients treated per year and drawing parallels to the lately discovered risks of sibutramine, another sympathomimetic with an overlapping mode of action and similar side effects on heart rate and blood pressure, we hypothesize that such a trial might be a dedicated risk mitigation strategy for public health. A critical assessment of cardiovascular side effects of MPH appears particularly warranted, because ADHD is associated with obesity, smoking and poor health in general. We summarize recent findings with the focus on cardiovascular risks of MPH in humans; we additionally analyze the limited number of rodent studies that have addressed cardiovascular risks of MPH.
Literatur
1.
3.
Zurück zum Zitat NIH (1998) NIH Consensus Statement. Diagnosis and treatment of attention deficit hyperactivity disorder (ADHD). NIH Consens Statement 16(2):1–37 NIH (1998) NIH Consensus Statement. Diagnosis and treatment of attention deficit hyperactivity disorder (ADHD). NIH Consens Statement 16(2):1–37
5.
Zurück zum Zitat Subcommittee on Attention-Deficit/Hyperactivity D, Steering Committee on Quality I, Management, Wolraich M, Brown L, Brown RT, DuPaul G, Earls M, Feldman HM, Ganiats TG, Kaplanek B, Meyer B, Perrin J, Pierce K, Reiff M, Stein MT, Visser S (2011) ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics 128(5):1007–1022. doi:10.1542/peds.2011-2654 Subcommittee on Attention-Deficit/Hyperactivity D, Steering Committee on Quality I, Management, Wolraich M, Brown L, Brown RT, DuPaul G, Earls M, Feldman HM, Ganiats TG, Kaplanek B, Meyer B, Perrin J, Pierce K, Reiff M, Stein MT, Visser S (2011) ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics 128(5):1007–1022. doi:10.​1542/​peds.​2011-2654
6.
Zurück zum Zitat Hinney A, Scherag A, Jarick I, Albayrak O, Putter C, Pechlivanis S, Dauvermann MR, Beck S, Weber H, Scherag S, Nguyen TT, Volckmar AL, Knoll N, Faraone SV, Neale BM, Franke B, Cichon S, Hoffmann P, Nothen MM, Schreiber S, Jockel KH, Wichmann HE, Freitag C, Lempp T, Meyer J, Gilsbach S, Herpertz-Dahlmann B, Sinzig J, Lehmkuhl G, Renner TJ, Warnke A, Romanos M, Lesch KP, Reif A, Schimmelmann BG, Hebebrand J, Psychiatric GCAs (2011) Genome-wide association study in German patients with attention deficit/hyperactivity disorder. Am J Med Genetics Part B Neuropsychiatr Genetics 156B(8):888–897. doi:10.1002/ajmg.b.31246 Hinney A, Scherag A, Jarick I, Albayrak O, Putter C, Pechlivanis S, Dauvermann MR, Beck S, Weber H, Scherag S, Nguyen TT, Volckmar AL, Knoll N, Faraone SV, Neale BM, Franke B, Cichon S, Hoffmann P, Nothen MM, Schreiber S, Jockel KH, Wichmann HE, Freitag C, Lempp T, Meyer J, Gilsbach S, Herpertz-Dahlmann B, Sinzig J, Lehmkuhl G, Renner TJ, Warnke A, Romanos M, Lesch KP, Reif A, Schimmelmann BG, Hebebrand J, Psychiatric GCAs (2011) Genome-wide association study in German patients with attention deficit/hyperactivity disorder. Am J Med Genetics Part B Neuropsychiatr Genetics 156B(8):888–897. doi:10.​1002/​ajmg.​b.​31246
7.
Zurück zum Zitat Franke B, Faraone SV, Asherson P, Buitelaar J, Bau CH, Ramos-Quiroga JA, Mick E, Grevet EH, Johansson S, Haavik J, Lesch KP, Cormand B, Reif A, International Multicentre persistent AC (2012) The genetics of attention deficit/hyperactivity disorder in adults, a review. Mol Psychiatry 17(10):960–987. doi:10.1038/mp.2011.138 Franke B, Faraone SV, Asherson P, Buitelaar J, Bau CH, Ramos-Quiroga JA, Mick E, Grevet EH, Johansson S, Haavik J, Lesch KP, Cormand B, Reif A, International Multicentre persistent AC (2012) The genetics of attention deficit/hyperactivity disorder in adults, a review. Mol Psychiatry 17(10):960–987. doi:10.​1038/​mp.​2011.​138
8.
Zurück zum Zitat Faraone SV, Doyle AE (2001) The nature and heritability of attention-deficit/hyperactivity disorder. Child Adolesc Psychiatric Clin N Am 10(2):299–316, viii–ix Faraone SV, Doyle AE (2001) The nature and heritability of attention-deficit/hyperactivity disorder. Child Adolesc Psychiatric Clin N Am 10(2):299–316, viii–ix
9.
Zurück zum Zitat Holtkamp K, Konrad K, Muller B, Heussen N, Herpertz S, Herpertz-Dahlmann B, Hebebrand J (2004) Overweight and obesity in children with attention-deficit/hyperactivity disorder. Int J Obes Relat Metab Disord 28(5):685–689. doi:10.1038/sj.ijo.0802623 PubMed Holtkamp K, Konrad K, Muller B, Heussen N, Herpertz S, Herpertz-Dahlmann B, Hebebrand J (2004) Overweight and obesity in children with attention-deficit/hyperactivity disorder. Int J Obes Relat Metab Disord 28(5):685–689. doi:10.​1038/​sj.​ijo.​0802623 PubMed
10.
Zurück zum Zitat Cortese S, Angriman M, Maffeis C, Isnard P, Konofal E, Lecendreux M, Purper-Ouakil D, Vincenzi B, Bernardina BD, Mouren MC (2008) Attention-deficit/hyperactivity disorder (ADHD) and obesity: a systematic review of the literature. Crit Rev Food Sci Nutr 48(6):524–537. doi:10.1080/10408390701540124 PubMed Cortese S, Angriman M, Maffeis C, Isnard P, Konofal E, Lecendreux M, Purper-Ouakil D, Vincenzi B, Bernardina BD, Mouren MC (2008) Attention-deficit/hyperactivity disorder (ADHD) and obesity: a systematic review of the literature. Crit Rev Food Sci Nutr 48(6):524–537. doi:10.​1080/​1040839070154012​4 PubMed
11.
Zurück zum Zitat Waring ME, Lapane KL (2008) Overweight in children and adolescents in relation to attention-deficit/hyperactivity disorder: results from a national sample. Pediatrics 122(1):e1–e6. doi:10.1542/peds.2007-1955 PubMed Waring ME, Lapane KL (2008) Overweight in children and adolescents in relation to attention-deficit/hyperactivity disorder: results from a national sample. Pediatrics 122(1):e1–e6. doi:10.​1542/​peds.​2007-1955 PubMed
12.
Zurück zum Zitat Byrd HC, Curtin C, Anderson SE (2013) Attention-deficit/hyperactivity disorder and obesity in US males and females, age 8–15 years: National Health and Nutrition Examination Survey 2001–2004. Pediatr Obes 8(6):445–453. doi:10.1111/j.2047-6310.2012.00124.x PubMed Byrd HC, Curtin C, Anderson SE (2013) Attention-deficit/hyperactivity disorder and obesity in US males and females, age 8–15 years: National Health and Nutrition Examination Survey 2001–2004. Pediatr Obes 8(6):445–453. doi:10.​1111/​j.​2047-6310.​2012.​00124.​x PubMed
13.
Zurück zum Zitat Albayrak O, Putter C, Volckmar AL, Cichon S, Hoffmann P, Nothen MM, Jockel KH, Schreiber S, Wichmann HE, Faraone SV, Neale BM, Herpertz-Dahlmann B, Lehmkuhl G, Sinzig J, Renner TJ, Romanos M, Warnke A, Lesch KP, Reif A, Schimmelmann BG, Scherag A, Hebebrand J, Hinney A, Psychiatric GCAS (2013) Common obesity risk alleles in childhood attention-deficit/hyperactivity disorder. Am J Med Genetics Part B Neuropsychiatr Genetics 162B(4):295–305. doi:10.1002/ajmg.b.32144 Albayrak O, Putter C, Volckmar AL, Cichon S, Hoffmann P, Nothen MM, Jockel KH, Schreiber S, Wichmann HE, Faraone SV, Neale BM, Herpertz-Dahlmann B, Lehmkuhl G, Sinzig J, Renner TJ, Romanos M, Warnke A, Lesch KP, Reif A, Schimmelmann BG, Scherag A, Hebebrand J, Hinney A, Psychiatric GCAS (2013) Common obesity risk alleles in childhood attention-deficit/hyperactivity disorder. Am J Med Genetics Part B Neuropsychiatr Genetics 162B(4):295–305. doi:10.​1002/​ajmg.​b.​32144
14.
Zurück zum Zitat Milberger S, Biederman J, Faraone SV, Chen L, Jones J (1997) ADHD is associated with early initiation of cigarette smoking in children and adolescents. J Am Acad Child Adolesc Psychiatry 36(1):37–44. doi:10.1097/00004583-199701000-00015 PubMed Milberger S, Biederman J, Faraone SV, Chen L, Jones J (1997) ADHD is associated with early initiation of cigarette smoking in children and adolescents. J Am Acad Child Adolesc Psychiatry 36(1):37–44. doi:10.​1097/​00004583-199701000-00015 PubMed
15.
16.
17.
Zurück zum Zitat Riley AW, Spiel G, Coghill D, Dopfner M, Falissard B, Lorenzo MJ, Preuss U, Ralston SJ, Group AS (2006) Factors related to health-related quality of life (HRQoL) among children with ADHD in Europe at entry into treatment. Eur Child Adolesc Psychiatry 15(Suppl 1):I38–I45. doi:10.1007/s00787-006-1006-9 PubMed Riley AW, Spiel G, Coghill D, Dopfner M, Falissard B, Lorenzo MJ, Preuss U, Ralston SJ, Group AS (2006) Factors related to health-related quality of life (HRQoL) among children with ADHD in Europe at entry into treatment. Eur Child Adolesc Psychiatry 15(Suppl 1):I38–I45. doi:10.​1007/​s00787-006-1006-9 PubMed
18.
Zurück zum Zitat Gillies D, Sinn J, Lad SS, Leach MJ, Ross MJ (2012) Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database Syst Rev 7:CD007986. doi:10.1002/14651858.CD007986.pub2 Gillies D, Sinn J, Lad SS, Leach MJ, Ross MJ (2012) Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database Syst Rev 7:CD007986. doi:10.​1002/​14651858.​CD007986.​pub2
19.
Zurück zum Zitat Knight LA, Rooney M, Chronis-Tuscano A (2008) Psychosocial treatments for attention-deficit/hyperactivity disorder. Curr Psychiatry Rep 10(5):412–418PubMed Knight LA, Rooney M, Chronis-Tuscano A (2008) Psychosocial treatments for attention-deficit/hyperactivity disorder. Curr Psychiatry Rep 10(5):412–418PubMed
20.
Zurück zum Zitat Sonuga-Barke EJ, Brandeis D, Cortese S, Daley D, Ferrin M, Holtmann M, Stevenson J, Danckaerts M, van der Oord S, Dopfner M, Dittmann RW, Simonoff E, Zuddas A, Banaschewski T, Buitelaar J, Coghill D, Hollis C, Konofal E, Lecendreux M, Wong IC, Sergeant J, European AGG (2013) Nonpharmacological interventions for ADHD: systematic review and meta-analyses of randomized controlled trials of dietary and psychological treatments. Am J Psychiatry 170(3):275–289. doi:10.1176/appi.ajp.2012.12070991 PubMed Sonuga-Barke EJ, Brandeis D, Cortese S, Daley D, Ferrin M, Holtmann M, Stevenson J, Danckaerts M, van der Oord S, Dopfner M, Dittmann RW, Simonoff E, Zuddas A, Banaschewski T, Buitelaar J, Coghill D, Hollis C, Konofal E, Lecendreux M, Wong IC, Sergeant J, European AGG (2013) Nonpharmacological interventions for ADHD: systematic review and meta-analyses of randomized controlled trials of dietary and psychological treatments. Am J Psychiatry 170(3):275–289. doi:10.​1176/​appi.​ajp.​2012.​12070991 PubMed
21.
Zurück zum Zitat Banaschewski T, Coghill D, Santosh P, Zuddas A, Asherson P, Buitelaar J, Danckaerts M, Dopfner M, Faraone SV, Rothenberger A, Sergeant J, Steinhausen HC, Sonuga-Barke EJ, Taylor E (2006) Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline. Eur Child Adolesc Psychiatry 15(8):476–495. doi:10.1007/s00787-006-0549-0 PubMed Banaschewski T, Coghill D, Santosh P, Zuddas A, Asherson P, Buitelaar J, Danckaerts M, Dopfner M, Faraone SV, Rothenberger A, Sergeant J, Steinhausen HC, Sonuga-Barke EJ, Taylor E (2006) Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline. Eur Child Adolesc Psychiatry 15(8):476–495. doi:10.​1007/​s00787-006-0549-0 PubMed
22.
Zurück zum Zitat Faraone SV, Buitelaar J (2010) Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adolesc Psychiatry 19(4):353–364. doi:10.1007/s00787-009-0054-3 PubMed Faraone SV, Buitelaar J (2010) Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adolesc Psychiatry 19(4):353–364. doi:10.​1007/​s00787-009-0054-3 PubMed
23.
Zurück zum Zitat Hanwella R, Senanayake M, de Silva V (2011) Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis. BMC psychiatry 11:176. doi:10.1186/1471-244X-11-176 PubMedCentralPubMed Hanwella R, Senanayake M, de Silva V (2011) Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis. BMC psychiatry 11:176. doi:10.​1186/​1471-244X-11-176 PubMedCentralPubMed
24.
Zurück zum Zitat Chai G, Governale L, McMahon AW, Trinidad JP, Staffa J, Murphy D (2012) Trends of outpatient prescription drug utilization in US children, 2002–2010. Pediatrics 130(1):23–31. doi:10.1542/peds.2011-2879 PubMed Chai G, Governale L, McMahon AW, Trinidad JP, Staffa J, Murphy D (2012) Trends of outpatient prescription drug utilization in US children, 2002–2010. Pediatrics 130(1):23–31. doi:10.​1542/​peds.​2011-2879 PubMed
25.
Zurück zum Zitat Schubert I, Koster I, Lehmkuhl G (2010) The changing prevalence of attention-deficit/hyperactivity disorder and methylphenidate prescriptions: a study of data from a random sample of insurees of the AOK Health Insurance Company in the German State of Hesse, 2000–2007. Deutsches Arztebl Int 107(36):615–621. doi:10.3238/arztebl.2010.0615 Schubert I, Koster I, Lehmkuhl G (2010) The changing prevalence of attention-deficit/hyperactivity disorder and methylphenidate prescriptions: a study of data from a random sample of insurees of the AOK Health Insurance Company in the German State of Hesse, 2000–2007. Deutsches Arztebl Int 107(36):615–621. doi:10.​3238/​arztebl.​2010.​0615
28.
29.
Zurück zum Zitat Burgard DA, Fuller R, Becker B, Ferrell R, Dinglasan-Panlilio MJ (2013) Potential trends in Attention Deficit Hyperactivity Disorder (ADHD) drug use on a college campus: wastewater analysis of amphetamine and ritalinic acid. Sci Total Environ 450–451:242–249. doi:10.1016/j.scitotenv.2013.02.020 PubMed Burgard DA, Fuller R, Becker B, Ferrell R, Dinglasan-Panlilio MJ (2013) Potential trends in Attention Deficit Hyperactivity Disorder (ADHD) drug use on a college campus: wastewater analysis of amphetamine and ritalinic acid. Sci Total Environ 450–451:242–249. doi:10.​1016/​j.​scitotenv.​2013.​02.​020 PubMed
30.
Zurück zum Zitat Drye LT, Scherer RW, Lanctot KL, Rosenberg PB, Herrmann N, Bachman D, Mintzer JE, Group AR (2013) Designing a trial to evaluate potential treatments for apathy in dementia: the apathy in dementia methylphenidate trial (ADMET). Am J Geriatr Psychiatry 21(6):549–559. doi:10.1016/j.jagp.2012.12.018 PubMed Drye LT, Scherer RW, Lanctot KL, Rosenberg PB, Herrmann N, Bachman D, Mintzer JE, Group AR (2013) Designing a trial to evaluate potential treatments for apathy in dementia: the apathy in dementia methylphenidate trial (ADMET). Am J Geriatr Psychiatry 21(6):549–559. doi:10.​1016/​j.​jagp.​2012.​12.​018 PubMed
31.
Zurück zum Zitat Kooij SJ, Bejerot S, Blackwell A, Caci H, Casas-Brugue M, Carpentier PJ, Edvinsson D, Fayyad J, Foeken K, Fitzgerald M, Gaillac V, Ginsberg Y, Henry C, Krause J, Lensing MB, Manor I, Niederhofer H, Nunes-Filipe C, Ohlmeier MD, Oswald P, Pallanti S, Pehlivanidis A, Ramos-Quiroga JA, Rastam M, Ryffel-Rawak D, Stes S, Asherson P (2010) European consensus statement on diagnosis and treatment of adult ADHD: the European Network Adult ADHD. BMC Psychiatry 10:67. doi:10.1186/1471-244X-10-67 PubMedCentralPubMed Kooij SJ, Bejerot S, Blackwell A, Caci H, Casas-Brugue M, Carpentier PJ, Edvinsson D, Fayyad J, Foeken K, Fitzgerald M, Gaillac V, Ginsberg Y, Henry C, Krause J, Lensing MB, Manor I, Niederhofer H, Nunes-Filipe C, Ohlmeier MD, Oswald P, Pallanti S, Pehlivanidis A, Ramos-Quiroga JA, Rastam M, Ryffel-Rawak D, Stes S, Asherson P (2010) European consensus statement on diagnosis and treatment of adult ADHD: the European Network Adult ADHD. BMC Psychiatry 10:67. doi:10.​1186/​1471-244X-10-67 PubMedCentralPubMed
32.
Zurück zum Zitat Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ, Comparative Risk Assessment Collaborating G (2002) Selected major risk factors and global and regional burden of disease. Lancet 360(9343):1347–1360. doi:10.1016/S0140-6736(02)11403-6 Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ, Comparative Risk Assessment Collaborating G (2002) Selected major risk factors and global and regional burden of disease. Lancet 360(9343):1347–1360. doi:10.​1016/​S0140-6736(02)11403-6
33.
Zurück zum Zitat NHBP-EPWG (2004) National high blood pressure education program working group on high blood pressure in children and adolescents: the fourth report on the diagnosis, evaluation and treatment of high blood pressure in children and adolescents. Pediatrics 114:555–576 NHBP-EPWG (2004) National high blood pressure education program working group on high blood pressure in children and adolescents: the fourth report on the diagnosis, evaluation and treatment of high blood pressure in children and adolescents. Pediatrics 114:555–576
34.
Zurück zum Zitat Neuhauser HK, Thamm M, Ellert U, Hense HW, Rosario AS (2011) Blood pressure percentiles by age and height from nonoverweight children and adolescents in Germany. Pediatrics 127(4):e978–e988. doi:10.1542/peds.2010-1290 PubMed Neuhauser HK, Thamm M, Ellert U, Hense HW, Rosario AS (2011) Blood pressure percentiles by age and height from nonoverweight children and adolescents in Germany. Pediatrics 127(4):e978–e988. doi:10.​1542/​peds.​2010-1290 PubMed
35.
Zurück zum Zitat Spagnolo A, Giussani M, Ambruzzi AM, Bianchetti M, Maringhini S, Matteucci MC, Menghetti E, Salice P, Simionato L, Strambi M, Virdis R, Genovesi S (2013) Focus on prevention, diagnosis and treatment of hypertension in children and adolescents. Ital J Pediatr 39:20. doi:10.1186/1824-7288-39-20 PubMedCentralPubMed Spagnolo A, Giussani M, Ambruzzi AM, Bianchetti M, Maringhini S, Matteucci MC, Menghetti E, Salice P, Simionato L, Strambi M, Virdis R, Genovesi S (2013) Focus on prevention, diagnosis and treatment of hypertension in children and adolescents. Ital J Pediatr 39:20. doi:10.​1186/​1824-7288-39-20 PubMedCentralPubMed
36.
Zurück zum Zitat Lurbe E, Cifkova R, Cruickshank JK, Dillon MJ, Ferreira I, Invitti C, Kuznetsova T, Laurent S, Mancia G, Morales-Olivas F, Rascher W, Redon J, Schaefer F, Seeman T, Stergiou G, Wuhl E, Zanchetti A, European Society of H (2009) Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension. J Hypertens 27(9):1719–1742. doi:10.1097/HJH.0b013e32832f4f6b Lurbe E, Cifkova R, Cruickshank JK, Dillon MJ, Ferreira I, Invitti C, Kuznetsova T, Laurent S, Mancia G, Morales-Olivas F, Rascher W, Redon J, Schaefer F, Seeman T, Stergiou G, Wuhl E, Zanchetti A, European Society of H (2009) Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension. J Hypertens 27(9):1719–1742. doi:10.​1097/​HJH.​0b013e32832f4f6b​
39.
Zurück zum Zitat Bao W, Threefoot SA, Srinivasan SR, Berenson GS (1995) Essential hypertension predicted by tracking of elevated blood pressure from childhood to adulthood: the Bogalusa Heart Study. Am J Hypertens 8(7):657–665. doi:10.1016/0895-7061(95)00116-7 PubMed Bao W, Threefoot SA, Srinivasan SR, Berenson GS (1995) Essential hypertension predicted by tracking of elevated blood pressure from childhood to adulthood: the Bogalusa Heart Study. Am J Hypertens 8(7):657–665. doi:10.​1016/​0895-7061(95)00116-7 PubMed
40.
Zurück zum Zitat Rascher W, Kiess W, Korner A (2013) High blood pressure in obese children and adolescents. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 56(4):492–499. doi:10.1007/s00103-012-1638-5 PubMed Rascher W, Kiess W, Korner A (2013) High blood pressure in obese children and adolescents. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 56(4):492–499. doi:10.​1007/​s00103-012-1638-5 PubMed
41.
Zurück zum Zitat Reinehr T, Wiegand S, Siegfried W, Keller KM, Widhalm K, l’Allemand D, Zwiauer K, Holl RW (2013) Comorbidities in overweight children and adolescents: do we treat them effectively? Int J Obes 37(4):493–499. doi:10.1038/ijo.2012.184 Reinehr T, Wiegand S, Siegfried W, Keller KM, Widhalm K, l’Allemand D, Zwiauer K, Holl RW (2013) Comorbidities in overweight children and adolescents: do we treat them effectively? Int J Obes 37(4):493–499. doi:10.​1038/​ijo.​2012.​184
42.
Zurück zum Zitat Giudice R, Izzo R, Manzi MV, Pagnano G, Santoro M, Rao MA, Di Renzo G, De Luca N, Trimarco V (2012) Lifestyle-related risk factors, smoking status and cardiovascular disease. High Blood Press Cardiovasc Prev 19(2):85–92. doi:10.2165/11632140-000000000-00000 PubMed Giudice R, Izzo R, Manzi MV, Pagnano G, Santoro M, Rao MA, Di Renzo G, De Luca N, Trimarco V (2012) Lifestyle-related risk factors, smoking status and cardiovascular disease. High Blood Press Cardiovasc Prev 19(2):85–92. doi:10.​2165/​11632140-000000000-00000 PubMed
43.
Zurück zum Zitat Rodrigues AN, Abreu GR, Resende RS, Goncalves WL, Gouvea SA (2013) Cardiovascular risk factor investigation: a pediatric issue. Int J General Med 6:57–66. doi:10.2147/IJGM.S41480 Rodrigues AN, Abreu GR, Resende RS, Goncalves WL, Gouvea SA (2013) Cardiovascular risk factor investigation: a pediatric issue. Int J General Med 6:57–66. doi:10.​2147/​IJGM.​S41480
44.
Zurück zum Zitat Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Hypertension E-ETFotMoA (2007) 2007 ESH-ESC practice guidelines for the management of arterial hypertension: ESH-ESC task force on the management of arterial hypertension. J Hypertens 25(9):1751–1762. doi:10.1097/HJH.0b013e3282f0580f PubMed Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Hypertension E-ETFotMoA (2007) 2007 ESH-ESC practice guidelines for the management of arterial hypertension: ESH-ESC task force on the management of arterial hypertension. J Hypertens 25(9):1751–1762. doi:10.​1097/​HJH.​0b013e3282f0580f​ PubMed
45.
Zurück zum Zitat Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Struijker Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Kjeldsen SE, Erdine S, Narkiewicz K, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Cifkova R, Dominiczak A, Fagard R, Heagerty AM, Laurent S, Lindholm LH, Mancia G, Manolis A, Nilsson PM, Redon J, Schmieder RE, Struijker-Boudier HA, Viigimaa M, Filippatos G, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Kiowski W, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O’Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Viigimaa M, Waeber B, Williams B, Zamorano JL, The task force for the management of arterial hypertension of the European Society of H, The task force for the management of arterial hypertension of the European Society of C (2007) 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 28(12):1462–1536. doi:10.1093/eurheartj/ehm236 Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Struijker Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Kjeldsen SE, Erdine S, Narkiewicz K, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Cifkova R, Dominiczak A, Fagard R, Heagerty AM, Laurent S, Lindholm LH, Mancia G, Manolis A, Nilsson PM, Redon J, Schmieder RE, Struijker-Boudier HA, Viigimaa M, Filippatos G, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Kiowski W, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O’Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Viigimaa M, Waeber B, Williams B, Zamorano JL, The task force for the management of arterial hypertension of the European Society of H, The task force for the management of arterial hypertension of the European Society of C (2007) 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 28(12):1462–1536. doi:10.​1093/​eurheartj/​ehm236
46.
Zurück zum Zitat Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ, Joint National Committee on Prevention DE, Treatment of High Blood Pressure. National Heart L, Blood I, National High Blood Pressure Education Program Coordinating C (2003) Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 42(6):1206–1252. doi:10.1161/01.HYP.0000107251.49515.c2 Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ, Joint National Committee on Prevention DE, Treatment of High Blood Pressure. National Heart L, Blood I, National High Blood Pressure Education Program Coordinating C (2003) Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 42(6):1206–1252. doi:10.​1161/​01.​HYP.​0000107251.​49515.​c2
47.
Zurück zum Zitat Whitworth JA, World Health Organization ISoHWG (2003) 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 21(11):1983–1992. doi:10.1097/01.hjh.0000084751.37215.d2 Whitworth JA, World Health Organization ISoHWG (2003) 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 21(11):1983–1992. doi:10.​1097/​01.​hjh.​0000084751.​37215.​d2
48.
Zurück zum Zitat Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, Sever PS, Mc GTS, British Hypertension S (2004) Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 18(3):139–185. doi:10.1038/sj.jhh.1001683 Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, Sever PS, Mc GTS, British Hypertension S (2004) Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 18(3):139–185. doi:10.​1038/​sj.​jhh.​1001683
49.
Zurück zum Zitat Carretero OA, Oparil S (2000) Essential hypertension. Part I: definition and etiology. Circulation 101(3):329–335PubMed Carretero OA, Oparil S (2000) Essential hypertension. Part I: definition and etiology. Circulation 101(3):329–335PubMed
50.
Zurück zum Zitat Erdine S, Ari O, Zanchetti A, Cifkova R, Fagard R, Kjeldsen S, Mancia G, Poulter N, Rahn KH, Rodicio JL, Ruilope LM, Staessen J, van Zwieten P, Waeber B, Williams B (2006) ESH-ESC guidelines for the management of hypertension. Herz 31(4):331–338. doi:10.1007/s00059-006-2829-3 PubMed Erdine S, Ari O, Zanchetti A, Cifkova R, Fagard R, Kjeldsen S, Mancia G, Poulter N, Rahn KH, Rodicio JL, Ruilope LM, Staessen J, van Zwieten P, Waeber B, Williams B (2006) ESH-ESC guidelines for the management of hypertension. Herz 31(4):331–338. doi:10.​1007/​s00059-006-2829-3 PubMed
51.
Zurück zum Zitat Arnold JM, Fitchett DH, Howlett JG, Lonn EM, Tardif JC (2008) Resting heart rate: a modifiable prognostic indicator of cardiovascular risk and outcomes? Can J Cardiol 24(Suppl A):3A–8A Arnold JM, Fitchett DH, Howlett JG, Lonn EM, Tardif JC (2008) Resting heart rate: a modifiable prognostic indicator of cardiovascular risk and outcomes? Can J Cardiol 24(Suppl A):3A–8A
52.
Zurück zum Zitat Dalby M, Gjesdal K (2012) Resting pulse rate as an indicator of health and disease. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 132(11):1348–1351. doi:10.4045/tidsskr.11.0629 Dalby M, Gjesdal K (2012) Resting pulse rate as an indicator of health and disease. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 132(11):1348–1351. doi:10.​4045/​tidsskr.​11.​0629
54.
Zurück zum Zitat Ostchega Y, Porter KS, Hughes J, Dillon CF, Nwankwo T (2011) Resting pulse rate reference data for children, adolescents, and adults: United States, 1999-2008. Natl Health Stat Rep 41:1–16 Ostchega Y, Porter KS, Hughes J, Dillon CF, Nwankwo T (2011) Resting pulse rate reference data for children, adolescents, and adults: United States, 1999-2008. Natl Health Stat Rep 41:1–16
55.
Zurück zum Zitat Stessman J, Jacobs JM, Stessman-Lande I, Gilon D, Leibowitz D (2013) Aging, resting pulse rate, and longevity. J Am Geriatr Soc 61(1):40–45. doi:10.1111/jgs.12060 PubMed Stessman J, Jacobs JM, Stessman-Lande I, Gilon D, Leibowitz D (2013) Aging, resting pulse rate, and longevity. J Am Geriatr Soc 61(1):40–45. doi:10.​1111/​jgs.​12060 PubMed
56.
Zurück zum Zitat Samuels JA, Franco K, Wan F, Sorof JM (2006) Effect of stimulants on 24-h ambulatory blood pressure in children with ADHD: a double-blind, randomized, cross-over trial. Pediatr Nephrol 21(1):92–95. doi:10.1007/s00467-005-2051-1 PubMed Samuels JA, Franco K, Wan F, Sorof JM (2006) Effect of stimulants on 24-h ambulatory blood pressure in children with ADHD: a double-blind, randomized, cross-over trial. Pediatr Nephrol 21(1):92–95. doi:10.​1007/​s00467-005-2051-1 PubMed
57.
Zurück zum Zitat Stowe CD, Gardner SF, Gist CC, Schulz EG, Wells TG (2002) 24-hour ambulatory blood pressure monitoring in male children receiving stimulant therapy. Ann Pharmacother 36(7–8):1142–1149PubMed Stowe CD, Gardner SF, Gist CC, Schulz EG, Wells TG (2002) 24-hour ambulatory blood pressure monitoring in male children receiving stimulant therapy. Ann Pharmacother 36(7–8):1142–1149PubMed
59.
Zurück zum Zitat McCarthy S, Cranswick N, Potts L, Taylor E, Wong IC (2009) Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment: a retrospective cohort study of children, adolescents and young adults using the general practice research database. Drug Saf 32(11):1089–1096. doi:10.2165/11317630-000000000-00000 PubMed McCarthy S, Cranswick N, Potts L, Taylor E, Wong IC (2009) Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment: a retrospective cohort study of children, adolescents and young adults using the general practice research database. Drug Saf 32(11):1089–1096. doi:10.​2165/​11317630-000000000-00000 PubMed
62.
Zurück zum Zitat Newstadt M (2006) To box OR NOT TO box. J Ky Med Assoc 104(8):344–345PubMed Newstadt M (2006) To box OR NOT TO box. J Ky Med Assoc 104(8):344–345PubMed
63.
Zurück zum Zitat Fegert JM, Hebebrand J, Kommission Entwicklungspsychopharmakologie der drei F (2006) [Attitude to questionable cadiac risks in stimulant administration]. Zeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie 34(4):295–297 Fegert JM, Hebebrand J, Kommission Entwicklungspsychopharmakologie der drei F (2006) [Attitude to questionable cadiac risks in stimulant administration]. Zeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie 34(4):295–297
64.
Zurück zum Zitat Hackford R (2006) With the recent Food and Drug Administration (FDA) Advisory Committee’s recommendation to put a black box warning on stimulants, the government has joined the media in raising alarm about the medical treatment of attention-deficit disorder. J Dev Behav Pediatr 27(2):179PubMed Hackford R (2006) With the recent Food and Drug Administration (FDA) Advisory Committee’s recommendation to put a black box warning on stimulants, the government has joined the media in raising alarm about the medical treatment of attention-deficit disorder. J Dev Behav Pediatr 27(2):179PubMed
66.
Zurück zum Zitat Gutgesell H, Atkins D, Barst R, Buck M, Franklin W, Humes R, Ringel R, Shaddy R, Taubert KA (1999) AHA Scientific Statement: cardiovascular monitoring of children and adolescents receiving psychotropic drugs. J Am Acad Child Adolesc Psychiatry 38(8):1047–1050. doi:10.1097/00004583-199908000-00022 PubMed Gutgesell H, Atkins D, Barst R, Buck M, Franklin W, Humes R, Ringel R, Shaddy R, Taubert KA (1999) AHA Scientific Statement: cardiovascular monitoring of children and adolescents receiving psychotropic drugs. J Am Acad Child Adolesc Psychiatry 38(8):1047–1050. doi:10.​1097/​00004583-199908000-00022 PubMed
67.
Zurück zum Zitat Gutgesell H, Atkins D, Barst R, Buck M, Franklin W, Humes R, Ringel R, Shaddy R, Taubert KA (1999) Cardiovascular monitoring of children and adolescents receiving psychotropic drugs: a statement for healthcare professionals from the Committee on Congenital Cardiac Defects, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 99(7):979–982PubMed Gutgesell H, Atkins D, Barst R, Buck M, Franklin W, Humes R, Ringel R, Shaddy R, Taubert KA (1999) Cardiovascular monitoring of children and adolescents receiving psychotropic drugs: a statement for healthcare professionals from the Committee on Congenital Cardiac Defects, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 99(7):979–982PubMed
69.
Zurück zum Zitat Winterstein AG, Gerhard T, Shuster J, Johnson M, Zito JM, Saidi A (2007) Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics 120(6):e1494–e1501. doi:10.1542/peds.2007-0675 PubMed Winterstein AG, Gerhard T, Shuster J, Johnson M, Zito JM, Saidi A (2007) Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics 120(6):e1494–e1501. doi:10.​1542/​peds.​2007-0675 PubMed
70.
Zurück zum Zitat Winterstein AG, Gerhard T, Shuster J, Saidi A (2009) Cardiac safety of methylphenidate versus amphetamine salts in the treatment of ADHD. Pediatrics 124(1):e75–e80. doi:10.1542/peds.2008-3138 PubMed Winterstein AG, Gerhard T, Shuster J, Saidi A (2009) Cardiac safety of methylphenidate versus amphetamine salts in the treatment of ADHD. Pediatrics 124(1):e75–e80. doi:10.​1542/​peds.​2008-3138 PubMed
71.
Zurück zum Zitat Winterstein AG, Gerhard T, Kubilis P, Saidi A, Linden S, Crystal S, Zito J, Shuster JJ, Olfson M (2012) Cardiovascular safety of central nervous system stimulants in children and adolescents: population based cohort study. BMJ 345:e4627. doi:10.1136/bmj.e4627 PubMedCentralPubMed Winterstein AG, Gerhard T, Kubilis P, Saidi A, Linden S, Crystal S, Zito J, Shuster JJ, Olfson M (2012) Cardiovascular safety of central nervous system stimulants in children and adolescents: population based cohort study. BMJ 345:e4627. doi:10.​1136/​bmj.​e4627 PubMedCentralPubMed
73.
Zurück zum Zitat Cooper WO, Habel LA, Sox CM, Chan KA, Arbogast PG, Cheetham TC, Murray KT, Quinn VP, Stein CM, Callahan ST, Fireman BH, Fish FA, Kirshner HS, O’Duffy A, Connell FA, Ray WA (2011) ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med 365(20):1896–1904. doi:10.1056/NEJMoa1110212 PubMed Cooper WO, Habel LA, Sox CM, Chan KA, Arbogast PG, Cheetham TC, Murray KT, Quinn VP, Stein CM, Callahan ST, Fireman BH, Fish FA, Kirshner HS, O’Duffy A, Connell FA, Ray WA (2011) ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med 365(20):1896–1904. doi:10.​1056/​NEJMoa1110212 PubMed
74.
Zurück zum Zitat Habel LA, Cooper WO, Sox CM, Chan KA, Fireman BH, Arbogast PG, Cheetham TC, Quinn VP, Dublin S, Boudreau DM, Andrade SE, Pawloski PA, Raebel MA, Smith DH, Achacoso N, Uratsu C, Go AS, Sidney S, Nguyen-Huynh MN, Ray WA, Selby JV (2011) ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA 306(24):2673–2683. doi:10.1001/jama.2011.1830 PubMedCentralPubMed Habel LA, Cooper WO, Sox CM, Chan KA, Fireman BH, Arbogast PG, Cheetham TC, Quinn VP, Dublin S, Boudreau DM, Andrade SE, Pawloski PA, Raebel MA, Smith DH, Achacoso N, Uratsu C, Go AS, Sidney S, Nguyen-Huynh MN, Ray WA, Selby JV (2011) ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA 306(24):2673–2683. doi:10.​1001/​jama.​2011.​1830 PubMedCentralPubMed
75.
Zurück zum Zitat Schelleman H, Bilker WB, Kimmel SE, Daniel GW, Newcomb C, Guevara JP, Cziraky MJ, Strom BL, Hennessy S (2012) Methylphenidate and risk of serious cardiovascular events in adults. Am J Psychiatry 169(2):178–185. doi:10.1176/appi.ajp.2011.11010125 PubMed Schelleman H, Bilker WB, Kimmel SE, Daniel GW, Newcomb C, Guevara JP, Cziraky MJ, Strom BL, Hennessy S (2012) Methylphenidate and risk of serious cardiovascular events in adults. Am J Psychiatry 169(2):178–185. doi:10.​1176/​appi.​ajp.​2011.​11010125 PubMed
76.
Zurück zum Zitat Schelleman H, Bilker WB, Strom BL, Kimmel SE, Newcomb C, Guevara JP, Daniel GW, Cziraky MJ, Hennessy S (2011) Cardiovascular events and death in children exposed and unexposed to ADHD agents. Pediatrics 127(6):1102–1110. doi:10.1542/peds.2010-3371 PubMedCentralPubMed Schelleman H, Bilker WB, Strom BL, Kimmel SE, Newcomb C, Guevara JP, Daniel GW, Cziraky MJ, Hennessy S (2011) Cardiovascular events and death in children exposed and unexposed to ADHD agents. Pediatrics 127(6):1102–1110. doi:10.​1542/​peds.​2010-3371 PubMedCentralPubMed
77.
Zurück zum Zitat Buchhorn R, Muller C, Willaschek C, Norozi K (2012) How to predict the impact of methylphenidate on cardiovascular risk in children with attention deficit disorder: methylphenidate improves autonomic dysfunction in children with ADHD. ISRN Pharmacol 170935. doi:10.5402/2012/170935 Buchhorn R, Muller C, Willaschek C, Norozi K (2012) How to predict the impact of methylphenidate on cardiovascular risk in children with attention deficit disorder: methylphenidate improves autonomic dysfunction in children with ADHD. ISRN Pharmacol 170935. doi:10.​5402/​2012/​170935
78.
Zurück zum Zitat Buchhorn R, Conzelmann A, Willaschek C, Stork D, Taurines R, Renner TJ (2012) Heart rate variability and methylphenidate in children with ADHD. Atten Deficit Hyperact Disord 4(2):85–91. doi:10.1007/s12402-012-0072-8 Buchhorn R, Conzelmann A, Willaschek C, Stork D, Taurines R, Renner TJ (2012) Heart rate variability and methylphenidate in children with ADHD. Atten Deficit Hyperact Disord 4(2):85–91. doi:10.​1007/​s12402-012-0072-8
79.
Zurück zum Zitat Rash JA, Aguirre-Camacho A (2012) Attention-deficit hyperactivity disorder and cardiac vagal control: a systematic review. Atten Deficit Hyperact Disord 4(4):167–177. doi:10.1007/s12402-012-0087-1 Rash JA, Aguirre-Camacho A (2012) Attention-deficit hyperactivity disorder and cardiac vagal control: a systematic review. Atten Deficit Hyperact Disord 4(4):167–177. doi:10.​1007/​s12402-012-0087-1
81.
Zurück zum Zitat Vetter VL, Elia J, Erickson C, Berger S, Blum N, Uzark K, Webb CL, American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects C, American Heart Association Council on Cardiovascular N (2008) Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. Circulation 117(18):2407–2423. doi:10.1161/CIRCULATIONAHA.107.189473 Vetter VL, Elia J, Erickson C, Berger S, Blum N, Uzark K, Webb CL, American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects C, American Heart Association Council on Cardiovascular N (2008) Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. Circulation 117(18):2407–2423. doi:10.​1161/​CIRCULATIONAHA.​107.​189473
82.
Zurück zum Zitat Graham J, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Dittmann RW, Dopfner M, Hamilton R, Hollis C, Holtmann M, Hulpke-Wette M, Lecendreux M, Rosenthal E, Rothenberger A, Santosh P, Sergeant J, Simonoff E, Sonuga-Barke E, Wong IC, Zuddas A, Steinhausen HC, Taylor E, European Guidelines G (2011) European guidelines on managing adverse effects of medication for ADHD. Eur Child Adolesc Psychiatry 20(1):17–37. doi:10.1007/s00787-010-0140-6 Graham J, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Dittmann RW, Dopfner M, Hamilton R, Hollis C, Holtmann M, Hulpke-Wette M, Lecendreux M, Rosenthal E, Rothenberger A, Santosh P, Sergeant J, Simonoff E, Sonuga-Barke E, Wong IC, Zuddas A, Steinhausen HC, Taylor E, European Guidelines G (2011) European guidelines on managing adverse effects of medication for ADHD. Eur Child Adolesc Psychiatry 20(1):17–37. doi:10.​1007/​s00787-010-0140-6
83.
Zurück zum Zitat Wilens TE, Hammerness PG, Biederman J, Kwon A, Spencer TJ, Clark S, Scott M, Podolski A, Ditterline JW, Morris MC, Moore H (2005) Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry 66(2):253–259PubMed Wilens TE, Hammerness PG, Biederman J, Kwon A, Spencer TJ, Clark S, Scott M, Podolski A, Ditterline JW, Morris MC, Moore H (2005) Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry 66(2):253–259PubMed
84.
Zurück zum Zitat Vitiello B, Elliott GR, Swanson JM, Arnold LE, Hechtman L, Abikoff H, Molina BS, Wells K, Wigal T, Jensen PS, Greenhill LL, Kaltman JR, Severe JB, Odbert C, Hur K, Gibbons R (2012) Blood pressure and heart rate over 10 years in the multimodal treatment study of children with ADHD. Am J Psychiatry 169(2):167–177. doi:10.1176/appi.ajp.2011.10111705 PubMedCentralPubMed Vitiello B, Elliott GR, Swanson JM, Arnold LE, Hechtman L, Abikoff H, Molina BS, Wells K, Wigal T, Jensen PS, Greenhill LL, Kaltman JR, Severe JB, Odbert C, Hur K, Gibbons R (2012) Blood pressure and heart rate over 10 years in the multimodal treatment study of children with ADHD. Am J Psychiatry 169(2):167–177. doi:10.​1176/​appi.​ajp.​2011.​10111705 PubMedCentralPubMed
85.
Zurück zum Zitat Molina BS, Hinshaw SP, Swanson JM, Arnold LE, Vitiello B, Jensen PS, Epstein JN, Hoza B, Hechtman L, Abikoff HB, Elliott GR, Greenhill LL, Newcorn JH, Wells KC, Wigal T, Gibbons RD, Hur K, Houck PR, Group MTAC (2009) The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study. J Am Acad Child Adolesc Psychiatry 48(5):484–500. doi:10.1097/CHI.0b013e31819c23d0 Molina BS, Hinshaw SP, Swanson JM, Arnold LE, Vitiello B, Jensen PS, Epstein JN, Hoza B, Hechtman L, Abikoff HB, Elliott GR, Greenhill LL, Newcorn JH, Wells KC, Wigal T, Gibbons RD, Hur K, Houck PR, Group MTAC (2009) The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study. J Am Acad Child Adolesc Psychiatry 48(5):484–500. doi:10.​1097/​CHI.​0b013e31819c23d0​
86.
Zurück zum Zitat Heal DJ, Pierce DM (2006) Methylphenidate and its isomers: their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system. CNS Drugs 20(9):713–738PubMed Heal DJ, Pierce DM (2006) Methylphenidate and its isomers: their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system. CNS Drugs 20(9):713–738PubMed
87.
Zurück zum Zitat Quinn D (2008) Does chirality matter? Pharmacodynamics of enantiomers of methylphenidate in patients with attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 28(3 Suppl 2):S62–S66. doi:10.1097/JCP.0b013e3181744aa6 PubMed Quinn D (2008) Does chirality matter? Pharmacodynamics of enantiomers of methylphenidate in patients with attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 28(3 Suppl 2):S62–S66. doi:10.​1097/​JCP.​0b013e3181744aa6​ PubMed
88.
Zurück zum Zitat Markowitz JS, DeVane CL, Pestreich LK, Patrick KS, Muniz R (2006) A comprehensive in vitro screening of d-, l-, and dl-threo-methylphenidate: an exploratory study. J Child adolescent Psychopharmacol 16(6):687–698. doi:10.1089/cap.2006.16.687 Markowitz JS, DeVane CL, Pestreich LK, Patrick KS, Muniz R (2006) A comprehensive in vitro screening of d-, l-, and dl-threo-methylphenidate: an exploratory study. J Child adolescent Psychopharmacol 16(6):687–698. doi:10.​1089/​cap.​2006.​16.​687
90.
Zurück zum Zitat Maxwell RA, Sylwestrowicz HD, Holland R, Schneider F, Daniel AI (1961) Some actions of methylphenidate on the vascular system, arterial tissue and the nictitating membrane. J Pharmacol Exp Ther 131:355–365PubMed Maxwell RA, Sylwestrowicz HD, Holland R, Schneider F, Daniel AI (1961) Some actions of methylphenidate on the vascular system, arterial tissue and the nictitating membrane. J Pharmacol Exp Ther 131:355–365PubMed
91.
Zurück zum Zitat Ishiguro Y, Morgan JP (1997) Biphasic inotropic effects of methamphetamine and methylphenidate on ferret papillary muscles. J Cardiovasc Pharmacol 30(6):744–749PubMed Ishiguro Y, Morgan JP (1997) Biphasic inotropic effects of methamphetamine and methylphenidate on ferret papillary muscles. J Cardiovasc Pharmacol 30(6):744–749PubMed
93.
Zurück zum Zitat Faraone SV, Biederman J, Roe C (2002) Comparative efficacy of Adderall and methylphenidate in attention-deficit/hyperactivity disorder: a meta-analysis. J Clin Psychopharmacol 22(5):468–473PubMed Faraone SV, Biederman J, Roe C (2002) Comparative efficacy of Adderall and methylphenidate in attention-deficit/hyperactivity disorder: a meta-analysis. J Clin Psychopharmacol 22(5):468–473PubMed
95.
Zurück zum Zitat Glaser PE, Thomas TC, Joyce BM, Castellanos FX, Gerhardt GA (2005) Differential effects of amphetamine isomers on dopamine release in the rat striatum and nucleus accumbens core. Psychopharmacology 178(2–3):250–258. doi:10.1007/s00213-004-2012-6 PubMed Glaser PE, Thomas TC, Joyce BM, Castellanos FX, Gerhardt GA (2005) Differential effects of amphetamine isomers on dopamine release in the rat striatum and nucleus accumbens core. Psychopharmacology 178(2–3):250–258. doi:10.​1007/​s00213-004-2012-6 PubMed
96.
Zurück zum Zitat Joyce BM, Glaser PE, Gerhardt GA (2007) Adderall produces increased striatal dopamine release and a prolonged time course compared to amphetamine isomers. Psychopharmacology 191(3):669–677. doi:10.1007/s00213-006-0550-9 PubMed Joyce BM, Glaser PE, Gerhardt GA (2007) Adderall produces increased striatal dopamine release and a prolonged time course compared to amphetamine isomers. Psychopharmacology 191(3):669–677. doi:10.​1007/​s00213-006-0550-9 PubMed
97.
Zurück zum Zitat Adler LA, Weisler RH, Goodman DW, Hamdani M, Niebler GE (2009) Short-term effects of lisdexamfetamine dimesylate on cardiovascular parameters in a 4-week clinical trial in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry 70(12):1652–1661. doi:10.4088/JCP.09m05335pur PubMed Adler LA, Weisler RH, Goodman DW, Hamdani M, Niebler GE (2009) Short-term effects of lisdexamfetamine dimesylate on cardiovascular parameters in a 4-week clinical trial in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry 70(12):1652–1661. doi:10.​4088/​JCP.​09m05335pur PubMed
98.
Zurück zum Zitat Mikkelsen E, Lake CR, Brown GL, Ziegler MG, Ebert MH (1981) The hyperactive child syndrome: peripheral sympathetic nervous system function and the effect of d-amphetamine. Psychiatry Res 4(2):157–169PubMed Mikkelsen E, Lake CR, Brown GL, Ziegler MG, Ebert MH (1981) The hyperactive child syndrome: peripheral sympathetic nervous system function and the effect of d-amphetamine. Psychiatry Res 4(2):157–169PubMed
100.
Zurück zum Zitat Sert A, Gokcen C, Aypar E, Odabas D (2012) Effects of atomoxetine on cardiovascular functions and on QT dispersion in children with attention deficit hyperactivity disorder. Cardiol Young 22(2):158–161. doi:10.1017/S1047951111001211 PubMed Sert A, Gokcen C, Aypar E, Odabas D (2012) Effects of atomoxetine on cardiovascular functions and on QT dispersion in children with attention deficit hyperactivity disorder. Cardiol Young 22(2):158–161. doi:10.​1017/​S104795111100121​1 PubMed
101.
Zurück zum Zitat Arcieri R, Germinario EA, Bonati M, Masi G, Zuddas A, Vella S, Chiarotti F, Panei P, Italian Attention-Deficit/Hyperactivity Disorder Regional Reference C (2012) Cardiovascular measures in children and adolescents with attention-deficit/hyperactivity disorder who are new users of methylphenidate and atomoxetine. J Child Adolesc Psychopharmacol 22(6):423–431 Arcieri R, Germinario EA, Bonati M, Masi G, Zuddas A, Vella S, Chiarotti F, Panei P, Italian Attention-Deficit/Hyperactivity Disorder Regional Reference C (2012) Cardiovascular measures in children and adolescents with attention-deficit/hyperactivity disorder who are new users of methylphenidate and atomoxetine. J Child Adolesc Psychopharmacol 22(6):423–431
104.
Zurück zum Zitat Bange F, Le Heuzey MF, Acquaviva E, Delorme R, Mouren MC (2014) Cardiovascular risks and management during attention deficit hyperactivity disorder treatment with methylphenidate. Archives de pediatrie: organe officiel de la Societe francaise de pediatrie 21(1):108–112. doi:10.1016/j.arcped.2013.11.001 Bange F, Le Heuzey MF, Acquaviva E, Delorme R, Mouren MC (2014) Cardiovascular risks and management during attention deficit hyperactivity disorder treatment with methylphenidate. Archives de pediatrie: organe officiel de la Societe francaise de pediatrie 21(1):108–112. doi:10.​1016/​j.​arcped.​2013.​11.​001
105.
Zurück zum Zitat (NTP) (1995) National Toxicology Program (NTP): Toxicology and Carcinogenesis Studies of Methylphenidate Hydrochloride (CAS No. 298-59-9) in F344/N rats and B6C3F1 mice (feed studies). Natl Toxicol Program Tech Rep Ser 439:1–299 (NTP) (1995) National Toxicology Program (NTP): Toxicology and Carcinogenesis Studies of Methylphenidate Hydrochloride (CAS No. 298-59-9) in F344/N rats and B6C3F1 mice (feed studies). Natl Toxicol Program Tech Rep Ser 439:1–299
106.
Zurück zum Zitat Wakamatsu A, Nomura S, Tate Y, Shimizu S, Harada Y (2009) Effects of methylphenidate hydrochloride on the cardiovascular system in vivo and in vitro: a safety pharmacology study. J Pharmacol Toxicol Methods 59(3):128–134. doi:10.1016/j.vascn.2009.01.003 PubMed Wakamatsu A, Nomura S, Tate Y, Shimizu S, Harada Y (2009) Effects of methylphenidate hydrochloride on the cardiovascular system in vivo and in vitro: a safety pharmacology study. J Pharmacol Toxicol Methods 59(3):128–134. doi:10.​1016/​j.​vascn.​2009.​01.​003 PubMed
107.
Zurück zum Zitat Witt KL, Malarkey DE, Hobbs CA, Davis JP, Kissling GE, Caspary W, Travlos G, Recio L (2010) No increases in biomarkers of genetic damage or pathological changes in heart and brain tissues in male rats administered methylphenidate hydrochloride (Ritalin) for 28 days. Environ Mol Mutagen 51(1):80–88. doi:10.1002/em.20515 PubMedCentralPubMed Witt KL, Malarkey DE, Hobbs CA, Davis JP, Kissling GE, Caspary W, Travlos G, Recio L (2010) No increases in biomarkers of genetic damage or pathological changes in heart and brain tissues in male rats administered methylphenidate hydrochloride (Ritalin) for 28 days. Environ Mol Mutagen 51(1):80–88. doi:10.​1002/​em.​20515 PubMedCentralPubMed
108.
Zurück zum Zitat Henderson TA, Fischer VW (1995) Effects of methylphenidate (Ritalin) on mammalian myocardial ultrastructure. The American journal of cardiovascular pathology 5(1):68–78PubMed Henderson TA, Fischer VW (1995) Effects of methylphenidate (Ritalin) on mammalian myocardial ultrastructure. The American journal of cardiovascular pathology 5(1):68–78PubMed
109.
Zurück zum Zitat Take G, Bahcelioglu M, Oktem H, Tunc E, Gozil R, Erdogan D, Calguner E, Helvacioglu F, Giray SG, Elmas C (2008) Dose-dependent immunohistochemical and ultrastructural changes after oral methylphenidate administration in rat heart tissue. Anat Histol Embryol 37(4):303–308. doi:10.1111/j.1439-0264.2008.00845.x PubMed Take G, Bahcelioglu M, Oktem H, Tunc E, Gozil R, Erdogan D, Calguner E, Helvacioglu F, Giray SG, Elmas C (2008) Dose-dependent immunohistochemical and ultrastructural changes after oral methylphenidate administration in rat heart tissue. Anat Histol Embryol 37(4):303–308. doi:10.​1111/​j.​1439-0264.​2008.​00845.​x PubMed
110.
Zurück zum Zitat Wilens TE, Biederman J, Lerner M, Concerta Study G (2004) Effects of once-daily osmotic-release methylphenidate on blood pressure and heart rate in children with attention-deficit/hyperactivity disorder: results from a one-year follow-up study. J Clin Psychopharmacol 24(1):36–41. doi:10.1097/01.jcp.0000106223.36344.df Wilens TE, Biederman J, Lerner M, Concerta Study G (2004) Effects of once-daily osmotic-release methylphenidate on blood pressure and heart rate in children with attention-deficit/hyperactivity disorder: results from a one-year follow-up study. J Clin Psychopharmacol 24(1):36–41. doi:10.​1097/​01.​jcp.​0000106223.​36344.​df
111.
Zurück zum Zitat Joyce PR, Nicholls MG, Donald RA (1984) Methylphenidate increases heart rate, blood pressure and plasma epinephrine in normal subjects. Life Sci 34(18):1707–1711PubMed Joyce PR, Nicholls MG, Donald RA (1984) Methylphenidate increases heart rate, blood pressure and plasma epinephrine in normal subjects. Life Sci 34(18):1707–1711PubMed
112.
Zurück zum Zitat Steinkellner T, Freissmuth M, Sitte HH, Montgomery T (2011) The ugly side of amphetamines: short- and long-term toxicity of 3,4-methylenedioxymethamphetamine (MDMA, ‘Ecstasy’), methamphetamine and D-amphetamine. Biol Chem 392(1–2):103–115. doi:10.1515/BC.2011.016 PubMed Steinkellner T, Freissmuth M, Sitte HH, Montgomery T (2011) The ugly side of amphetamines: short- and long-term toxicity of 3,4-methylenedioxymethamphetamine (MDMA, ‘Ecstasy’), methamphetamine and D-amphetamine. Biol Chem 392(1–2):103–115. doi:10.​1515/​BC.​2011.​016 PubMed
113.
Zurück zum Zitat Simpson LL (1975) Blood pressure and heart rate responses evoked by d- and l-amphetamine in the pithed rat preparation. J Pharmacol Exp Ther 193(1):149–159PubMed Simpson LL (1975) Blood pressure and heart rate responses evoked by d- and l-amphetamine in the pithed rat preparation. J Pharmacol Exp Ther 193(1):149–159PubMed
114.
Zurück zum Zitat Tontodonati M, Fasdelli N, Moscardo E, Giarola A, Dorigatti R (2007) A canine model used to simultaneously assess potential neurobehavioural and cardiovascular effects of candidate drugs. J Pharmacol Toxicol Methods 56(2):265–275. doi:10.1016/j.vascn.2007.03.005 PubMed Tontodonati M, Fasdelli N, Moscardo E, Giarola A, Dorigatti R (2007) A canine model used to simultaneously assess potential neurobehavioural and cardiovascular effects of candidate drugs. J Pharmacol Toxicol Methods 56(2):265–275. doi:10.​1016/​j.​vascn.​2007.​03.​005 PubMed
115.
Zurück zum Zitat Goldstein DS, Nurnberger J Jr, Simmons S, Gershon ES, Polinsky R, Keiser HR (1983) Effects of injected sympathomimetic amines on plasma catecholamines and circulatory variables in man. Life Sci 32(10):1057–1063PubMed Goldstein DS, Nurnberger J Jr, Simmons S, Gershon ES, Polinsky R, Keiser HR (1983) Effects of injected sympathomimetic amines on plasma catecholamines and circulatory variables in man. Life Sci 32(10):1057–1063PubMed
116.
Zurück zum Zitat Volkow ND, Wang GJ, Fowler JS, Molina PE, Logan J, Gatley SJ, Gifford A, Ding YS, Wong C, Pappas NR, Zhu W, Swanson JM (2003) Cardiovascular effects of methylphenidate in humans are associated with increases of dopamine in brain and of epinephrine in plasma. Psychopharmacology 166(3):264–270. doi:10.1007/s00213-002-1340-7 PubMed Volkow ND, Wang GJ, Fowler JS, Molina PE, Logan J, Gatley SJ, Gifford A, Ding YS, Wong C, Pappas NR, Zhu W, Swanson JM (2003) Cardiovascular effects of methylphenidate in humans are associated with increases of dopamine in brain and of epinephrine in plasma. Psychopharmacology 166(3):264–270. doi:10.​1007/​s00213-002-1340-7 PubMed
117.
Zurück zum Zitat Thomas F, Blacher J, Benetos A, Safar ME, Pannier B (2008) Cardiovascular risk as defined in the 2003 European blood pressure classification: the assessment of an additional predictive value of pulse pressure on mortality. J Hypertens 26(6):1072–1077. doi:10.1097/HJH.0b013e3282fcc22b PubMed Thomas F, Blacher J, Benetos A, Safar ME, Pannier B (2008) Cardiovascular risk as defined in the 2003 European blood pressure classification: the assessment of an additional predictive value of pulse pressure on mortality. J Hypertens 26(6):1072–1077. doi:10.​1097/​HJH.​0b013e3282fcc22b​ PubMed
119.
Zurück zum Zitat Cacoub PP, Zeymer U, Limbourg T, Baumgartner I, Poldermans D, Rother J, Bhatt DL, Steg PG, Investigators RR (2011) Effects of adherence to guidelines for the control of major cardiovascular risk factors on outcomes in the REduction of Atherothrombosis for Continued Health (REACH) Registry Europe. Heart 97(8):660–667. doi:10.1136/hrt.2010.213710 PubMed Cacoub PP, Zeymer U, Limbourg T, Baumgartner I, Poldermans D, Rother J, Bhatt DL, Steg PG, Investigators RR (2011) Effects of adherence to guidelines for the control of major cardiovascular risk factors on outcomes in the REduction of Atherothrombosis for Continued Health (REACH) Registry Europe. Heart 97(8):660–667. doi:10.​1136/​hrt.​2010.​213710 PubMed
122.
Zurück zum Zitat Heal DJ, Aspley S, Prow MR, Jackson HC, Martin KF, Cheetham SC (1998) Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine. Int J Obes Relat Metab Disord 22(Suppl 1):S18–S28; discussion S29 Heal DJ, Aspley S, Prow MR, Jackson HC, Martin KF, Cheetham SC (1998) Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine. Int J Obes Relat Metab Disord 22(Suppl 1):S18–S28; discussion S29
123.
Zurück zum Zitat Nisoli E, Carruba MO (2000) An assessment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action. Obes Rev 1(2):127–139PubMed Nisoli E, Carruba MO (2000) An assessment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action. Obes Rev 1(2):127–139PubMed
126.
Zurück zum Zitat Schlaich MP, Lambert E, Kaye DM, Krozowski Z, Campbell DJ, Lambert G, Hastings J, Aggarwal A, Esler MD (2004) Sympathetic augmentation in hypertension: role of nerve firing, norepinephrine reuptake, and Angiotensin neuromodulation. Hypertension 43(2):169–175. doi:10.1161/01.HYP.0000103160.35395.9E PubMed Schlaich MP, Lambert E, Kaye DM, Krozowski Z, Campbell DJ, Lambert G, Hastings J, Aggarwal A, Esler MD (2004) Sympathetic augmentation in hypertension: role of nerve firing, norepinephrine reuptake, and Angiotensin neuromodulation. Hypertension 43(2):169–175. doi:10.​1161/​01.​HYP.​0000103160.​35395.​9E PubMed
127.
Zurück zum Zitat Heusser K, Tank J, Diedrich A, Engeli S, Klaua S, Kruger N, Strauss A, Stoffels G, Luft FC, Jordan J (2006) Influence of sibutramine treatment on sympathetic vasomotor tone in obese subjects. Clin Pharmacol Ther 79(5):500–508. doi:10.1016/j.clpt.2006.02.002 PubMed Heusser K, Tank J, Diedrich A, Engeli S, Klaua S, Kruger N, Strauss A, Stoffels G, Luft FC, Jordan J (2006) Influence of sibutramine treatment on sympathetic vasomotor tone in obese subjects. Clin Pharmacol Ther 79(5):500–508. doi:10.​1016/​j.​clpt.​2006.​02.​002 PubMed
128.
Zurück zum Zitat Heusser K, Engeli S, Tank J, Diedrich A, Wiesner S, Janke J, Luft FC, Jordan J (2007) Sympathetic vasomotor tone determines blood pressure response to long-term sibutramine treatment. J Clin Endocrinol Metab 92(4):1560–1563. doi:10.1210/jc.2006-2499 PubMed Heusser K, Engeli S, Tank J, Diedrich A, Wiesner S, Janke J, Luft FC, Jordan J (2007) Sympathetic vasomotor tone determines blood pressure response to long-term sibutramine treatment. J Clin Endocrinol Metab 92(4):1560–1563. doi:10.​1210/​jc.​2006-2499 PubMed
129.
Zurück zum Zitat WPT J (2005) The SCOUT study: risk-benefit profile of sibutramine in overweight high-risk cardiovascular patients. Euro Heart J Suppl 7(Supplement L):L44–L48 WPT J (2005) The SCOUT study: risk-benefit profile of sibutramine in overweight high-risk cardiovascular patients. Euro Heart J Suppl 7(Supplement L):L44–L48
130.
Zurück zum Zitat Westover AN, Nakonezny PA, Winhusen T, Adinoff B, Vongpatanasin W (2013) Risk of methylphenidate-induced prehypertension in normotensive adult smokers with attention deficit hyperactivity disorder. J Clin Hypertens 15(2):124–132. doi:10.1111/jch.12039 Westover AN, Nakonezny PA, Winhusen T, Adinoff B, Vongpatanasin W (2013) Risk of methylphenidate-induced prehypertension in normotensive adult smokers with attention deficit hyperactivity disorder. J Clin Hypertens 15(2):124–132. doi:10.​1111/​jch.​12039
132.
Zurück zum Zitat Scholze J (2002) Sibutramine in clinical practice—a PMS-study with positive effects on blood pressure and metabolic parameters. Dtsch Med Wochenschr 127(12):606–610. doi:10.1055/s-2002-22671 PubMed Scholze J (2002) Sibutramine in clinical practice—a PMS-study with positive effects on blood pressure and metabolic parameters. Dtsch Med Wochenschr 127(12):606–610. doi:10.​1055/​s-2002-22671 PubMed
133.
Zurück zum Zitat James WP, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni AP, Torp-Pedersen C, Sharma AM, Shepherd GM, Rode RA, Renz CL, Investigators S (2010) Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 363(10):905–917. doi:10.1056/NEJMoa1003114 PubMed James WP, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni AP, Torp-Pedersen C, Sharma AM, Shepherd GM, Rode RA, Renz CL, Investigators S (2010) Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 363(10):905–917. doi:10.​1056/​NEJMoa1003114 PubMed
134.
Zurück zum Zitat Van Gaal LF, Caterson ID, Coutinho W, Finer N, Maggioni AP, Sharma AM, Torp-Pedersen C, Ge H, Moran SA, Shepherd GM, James WP, Investigators S (2010) Weight and blood pressure response to weight management and sibutramine in diabetic and non-diabetic high-risk patients: an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes (SCOUT) trial. Diabetes Obes Metab 12(1):26–34. doi:10.1111/j.1463-1326.2009.01090.x PubMed Van Gaal LF, Caterson ID, Coutinho W, Finer N, Maggioni AP, Sharma AM, Torp-Pedersen C, Ge H, Moran SA, Shepherd GM, James WP, Investigators S (2010) Weight and blood pressure response to weight management and sibutramine in diabetic and non-diabetic high-risk patients: an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes (SCOUT) trial. Diabetes Obes Metab 12(1):26–34. doi:10.​1111/​j.​1463-1326.​2009.​01090.​x PubMed
135.
Zurück zum Zitat Sharma AM, Caterson ID, Coutinho W, Finer N, Van Gaal L, Maggioni AP, Torp-Pedersen C, Bacher HP, Shepherd GM, James WP, Investigators S (2009) Blood pressure changes associated with sibutramine and weight management—an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT). Diabetes Obes Metab 11(3):239–250. doi:10.1111/j.1463-1326.2008.00930.x Sharma AM, Caterson ID, Coutinho W, Finer N, Van Gaal L, Maggioni AP, Torp-Pedersen C, Bacher HP, Shepherd GM, James WP, Investigators S (2009) Blood pressure changes associated with sibutramine and weight management—an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT). Diabetes Obes Metab 11(3):239–250. doi:10.​1111/​j.​1463-1326.​2008.​00930.​x
136.
138.
Zurück zum Zitat Pollack A (2010) Abbott labs withdraws meridia from market. The New York Times (October 8th) Pollack A (2010) Abbott labs withdraws meridia from market. The New York Times (October 8th)
141.
Zurück zum Zitat Smith ME, Farah MJ (2011) Are prescription stimulants “smart pills”? The epidemiology and cognitive neuroscience of prescription stimulant use by normal healthy individuals. Psychol Bull 137(5):717–741. doi:10.1037/a0023825 PubMedCentralPubMed Smith ME, Farah MJ (2011) Are prescription stimulants “smart pills”? The epidemiology and cognitive neuroscience of prescription stimulant use by normal healthy individuals. Psychol Bull 137(5):717–741. doi:10.​1037/​a0023825 PubMedCentralPubMed
142.
143.
Zurück zum Zitat Prasad V, Brogan E, Mulvaney C, Grainge M, Stanton W, Sayal K (2013) How effective are drug treatments for children with ADHD at improving on-task behaviour and academic achievement in the school classroom? A systematic review and meta-analysis. Eur Child Adolesc Psychiatry 22(4):203–216. doi:10.1007/s00787-012-0346-x PubMed Prasad V, Brogan E, Mulvaney C, Grainge M, Stanton W, Sayal K (2013) How effective are drug treatments for children with ADHD at improving on-task behaviour and academic achievement in the school classroom? A systematic review and meta-analysis. Eur Child Adolesc Psychiatry 22(4):203–216. doi:10.​1007/​s00787-012-0346-x PubMed
144.
Zurück zum Zitat Langberg JM, Becker SP (2012) Does long-term medication use improve the academic outcomes of youth with attention-deficit/hyperactivity disorder? Clin Child Fam Psychol Rev 15(3):215–233. doi:10.1007/s10567-012-0117-8 PubMed Langberg JM, Becker SP (2012) Does long-term medication use improve the academic outcomes of youth with attention-deficit/hyperactivity disorder? Clin Child Fam Psychol Rev 15(3):215–233. doi:10.​1007/​s10567-012-0117-8 PubMed
145.
Zurück zum Zitat Shaw M, Hodgkins P, Caci H, Young S, Kahle J, Woods AG, Arnold LE (2012) A systematic review and analysis of long-term outcomes in attention deficit hyperactivity disorder: effects of treatment and non-treatment. BMC Med 10:99. doi:10.1186/1741-7015-10-99 PubMedCentralPubMed Shaw M, Hodgkins P, Caci H, Young S, Kahle J, Woods AG, Arnold LE (2012) A systematic review and analysis of long-term outcomes in attention deficit hyperactivity disorder: effects of treatment and non-treatment. BMC Med 10:99. doi:10.​1186/​1741-7015-10-99 PubMedCentralPubMed
146.
Zurück zum Zitat Bogle KE, Smith BH (2009) Illicit methylphenidate use: a review of prevalence, availability, pharmacology, and consequences. Curr Drug Abuse Rev 2(2):157–176PubMed Bogle KE, Smith BH (2009) Illicit methylphenidate use: a review of prevalence, availability, pharmacology, and consequences. Curr Drug Abuse Rev 2(2):157–176PubMed
147.
Zurück zum Zitat Davis C, Fattore L, Kaplan AS, Carter JC, Levitan RD, Kennedy JL (2012) The suppression of appetite and food consumption by methylphenidate: the moderating effects of gender and weight status in healthy adults. Int J Neuropsychopharmacol 15(2):181–187. doi:10.1017/S1461145711001039 PubMed Davis C, Fattore L, Kaplan AS, Carter JC, Levitan RD, Kennedy JL (2012) The suppression of appetite and food consumption by methylphenidate: the moderating effects of gender and weight status in healthy adults. Int J Neuropsychopharmacol 15(2):181–187. doi:10.​1017/​S146114571100103​9 PubMed
148.
Zurück zum Zitat Poulton A, Briody J, McCorquodale T, Melzer E, Herrmann M, Baur LA, Duque G (2012) Weight loss on stimulant medication: how does it affect body composition and bone metabolism?—a prospective longitudinal study. Int J Pediatr Endocrinol 1:30. doi:10.1186/1687-9856-2012-30 Poulton A, Briody J, McCorquodale T, Melzer E, Herrmann M, Baur LA, Duque G (2012) Weight loss on stimulant medication: how does it affect body composition and bone metabolism?—a prospective longitudinal study. Int J Pediatr Endocrinol 1:30. doi:10.​1186/​1687-9856-2012-30
149.
Zurück zum Zitat Ginsberg Y, Langstrom N, Larsson H, Lichtenstein P (2013) ADHD and criminality: could treatment benefit prisoners with ADHD who are at higher risk of reoffending? Expert Rev Neurother 13(4):345–348. doi:10.1586/ern.13.22 PubMed Ginsberg Y, Langstrom N, Larsson H, Lichtenstein P (2013) ADHD and criminality: could treatment benefit prisoners with ADHD who are at higher risk of reoffending? Expert Rev Neurother 13(4):345–348. doi:10.​1586/​ern.​13.​22 PubMed
150.
Zurück zum Zitat Padala PR, Burke WJ, Shostrom VK, Bhatia SC, Wengel SP, Potter JF, Petty F (2010) Methylphenidate for apathy and functional status in dementia of the Alzheimer type. Am J Geriatr Psychiatry 18(4):371–374. doi:10.1097/JGP.0b013e3181cabcf6 PubMed Padala PR, Burke WJ, Shostrom VK, Bhatia SC, Wengel SP, Potter JF, Petty F (2010) Methylphenidate for apathy and functional status in dementia of the Alzheimer type. Am J Geriatr Psychiatry 18(4):371–374. doi:10.​1097/​JGP.​0b013e3181cabcf6​ PubMed
151.
Zurück zum Zitat Martinez-Raga J, Knecht C, Szerman N, Martinez MI (2013) Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder. CNS Drugs 27(1):15–30. doi:10.1007/s40263-012-0019-9 PubMed Martinez-Raga J, Knecht C, Szerman N, Martinez MI (2013) Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder. CNS Drugs 27(1):15–30. doi:10.​1007/​s40263-012-0019-9 PubMed
152.
Zurück zum Zitat Leslie LK, Rodday AM, Saunders TS, Cohen JT, Wong JB, Sheldrick RC, Parsons SK (2012) Survey of United States child and adolescent psychiatrists’ cardiac screening practices prior to starting patients on stimulants. J Child Adolesc Psychopharmacol 22(5):375–384. doi:10.1089/cap.2011.0141 PubMedCentralPubMed Leslie LK, Rodday AM, Saunders TS, Cohen JT, Wong JB, Sheldrick RC, Parsons SK (2012) Survey of United States child and adolescent psychiatrists’ cardiac screening practices prior to starting patients on stimulants. J Child Adolesc Psychopharmacol 22(5):375–384. doi:10.​1089/​cap.​2011.​0141 PubMedCentralPubMed
153.
Zurück zum Zitat Lindemann C, Langner I, Kraut AA, Banaschewski T, Schad-Hansjosten T, Petermann U, Petermann F, Schreyer-Mehlhop I, Garbe E, Mikolajczyk RT (2012) Age-specific prevalence, incidence of new diagnoses, and drug treatment of attention-deficit/hyperactivity disorder in Germany. Child Adolesc Psychopharmacol 22(4):307–314 Lindemann C, Langner I, Kraut AA, Banaschewski T, Schad-Hansjosten T, Petermann U, Petermann F, Schreyer-Mehlhop I, Garbe E, Mikolajczyk RT (2012) Age-specific prevalence, incidence of new diagnoses, and drug treatment of attention-deficit/hyperactivity disorder in Germany. Child Adolesc Psychopharmacol 22(4):307–314
154.
Zurück zum Zitat Ford T, Goodman R, Meltzer H (2003) The British Child and Adolescent Mental Health Survey 1999: the prevalence of DSM-IV disorders. J Am Acad Child Adolesc Psychiatry 42(10):1203–1211PubMed Ford T, Goodman R, Meltzer H (2003) The British Child and Adolescent Mental Health Survey 1999: the prevalence of DSM-IV disorders. J Am Acad Child Adolesc Psychiatry 42(10):1203–1211PubMed
155.
Zurück zum Zitat McCarthy S, Wilton L, Murray ML, Hodgkins P, Asherson P, Wong IC (2012) The epidemiology of pharmacologically treated attention deficit hyperactivity disorder (ADHD) in children, adolescents and adults in UK primary care. BMC Pediatr 12:78PubMedCentralPubMed McCarthy S, Wilton L, Murray ML, Hodgkins P, Asherson P, Wong IC (2012) The epidemiology of pharmacologically treated attention deficit hyperactivity disorder (ADHD) in children, adolescents and adults in UK primary care. BMC Pediatr 12:78PubMedCentralPubMed
Metadaten
Titel
Assessment of potential cardiovascular risks of methylphenidate in comparison with sibutramine: do we need a SCOUT (trial)?
verfasst von
Jochen Antel
Özgür Albayrak
Gerd Heusch
Tobias Banaschewski
Johannes Hebebrand
Publikationsdatum
01.04.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
European Archives of Psychiatry and Clinical Neuroscience / Ausgabe 3/2015
Print ISSN: 0940-1334
Elektronische ISSN: 1433-8491
DOI
https://doi.org/10.1007/s00406-014-0522-8

Weitere Artikel der Ausgabe 3/2015

European Archives of Psychiatry and Clinical Neuroscience 3/2015 Zur Ausgabe

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.